Update shared on27 Aug 2025
Fair value Decreased 1.08%Despite a notable improvement in consensus revenue growth forecasts, Astellas Pharma’s fair value was revised only slightly lower, with the analyst price target decreasing marginally from ¥1711 to ¥1692.
What's in the News
- Positive Phase 3 EV-303 trial results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer show clinically meaningful improvements in event-free and overall survival versus surgery alone.
- Astellas and Pfizer report positive overall survival results from the Phase 3 EMBARK trial of XTANDI (enzalutamide) plus leuprolide in non-metastatic hormone-sensitive prostate cancer with high risk for metastasis; XTANDI monotherapy trend positive but not statistically significant.
- XTANDI (enzalutamide) newly funded under Ontario's Exceptional Access Program for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence; now publicly reimbursed in Ontario for all approved indications.
- U.S. sales of IZERVAY (avacincaptad pegol) for geographic atrophy secondary to age-related macular degeneration reached ¥15.9 billion / $110 million in Q1 FY2025, supporting financial performance.
- Astellas signed memorandums of understanding with Korea Institute of Startup and Entrepreneurship Development and Mitsubishi Research Institute to support Korean and Japanese drug-discovery startups, providing access to research facilities, expert consultation, and global networking opportunities.
Valuation Changes
Summary of Valuation Changes for Astellas Pharma
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from ¥1711 to ¥1692.
- The Consensus Revenue Growth forecasts for Astellas Pharma has significantly risen from -1.8% per annum to -1.4% per annum.
- The Future P/E for Astellas Pharma remained effectively unchanged, moving only marginally from 19.70x to 19.48x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.